Monday 14th November 2022 | 1.05pm BST
Ultimately we need to be bringing significant innovation to patients and supporting physicians to radically change treatment protocols - but does the industry skew too much towards what makes most financial sense? In this panel, Nick Keher will discuss whether ‘hot therapeutic areas of investor focus are a help or a hindrance to innovation’.
Nick joined Benevolent AI as CFO in March 2022, having previously been CFO of Clinigen, a UK AIM listed Global Pharmaceutical and Pharma Services company with over £450m of revenue. Prior to this Nick was an equity analyst covering the European healthcare space for over eight years, first at Investec and then at RBC where he was Managing Director and Head of RBC’s European healthcare equity research team. Nick began his career at Lloyd’s Pharmacy, registering as a pharmacist before joining GlaxoSmithKline (‘GSK’) where he completed his accountancy qualification (ACMA) working within GSK’s finance function